<DOC>
	<DOCNO>NCT01909245</DOCNO>
	<brief_summary>City Hope National Medical Center , locate Duarte , CA , host clinical study islet cell transplantation , experimental procedure evaluate treatment patient type 1 diabetes . Islet cell transplantation involve take insulin-producing cell organ donor transplant liver patient diabetes . Once transplant , islet produce insulin , improve blood sugar control eliminate need inject insulin use insulin pump . Anti-thymocyte globulin ( ATG ) anti-rejection medication work decrease patient 's T-cells . T-cells special white blood cell recognize destroy unwanted thing like infection also attack transplanted cell organ . Reducing number T-cells time transplant expect protect islet improve long-term transplant result . Transplant program around world see improve islet transplant result use T-cell depleting medication . Approximately 5-6 every 10 patient remain insulin five year transplant . These result similar achieve whole pancreas transplant without require major surgery , therefore , may option patient eligible whole pancreas transplant . The purpose study determine islet cell transplantation use ATG , along additional medication prevent body reject transplanted cell , safe effective treatment type 1 diabetes . Study participant may receive three islet transplant follow five year monitor blood sugar control , islet transplant function , change quality life .</brief_summary>
	<brief_title>Islet Cell Transplant Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>Three different category patient Type 1 Diabetes consider study participation : Naïve islet transplant alone ( nITA ) candidate : T1D patient complicate frequent hypoglycemia AND/OR hypoglycemia unawareness receive previous transplant kind . Repeat transplant ( RT ) candidate : T1D patient receive two few previous islet transplant &gt; 1 month prior screening , continue require exogenous insulin treatment HbA1c &gt; 6.5 % OR T1D patient history fail pancreas transplant &gt; 6 month prior screen . Islet kidney transplant ( IAK ) candidate : T1D patient history successful renal transplant &gt; 3 month prior screen Inclusion criterion candidate : 1 . Age 1868 year 2 . Type 1 diabetes mellitus 3 . Ability willingness comply posttransplant regimen Additional Inclusion Criteria nITA Candidates Only 4 . Frequent hypoglycemia ( blood glucose ≤ 54 mg/dl per week ) OR Hypoglycemia unawareness ( Clarke score 4 ) OR One severe hypoglycemic episode 12 month precede enrollment . Additional Inclusion Criteria RT Candidates Only 5 . Failed pancreas transplant &gt; 6 month prior screen OR Two few previous islet transplant &gt; 1 month prior screen continue exogenous insulin requirement and/or HbA1c &gt; 6.5 % Additional Inclusion Criteria IAK Candidates Only 6 . Successful renal transplant &gt; 3 month prior screen 7 . Stable maintenance immunosuppression consist tacrolimus alone conjunction sirolimus , mycophenolate mofetil , myfortic azathoprine ; cyclosporine conjunction sirolimus , mycophenolate mofetil , myfortic +/ ≤ 10 mg/day corticosteroid . 8 . No history acute rejection relate renal graft last 12 month low risk rejection 9 . Under continue care transplant nephrologist surgeon 1 . Body Mass Index ( BMI ) &gt; 30 2 . Insulin requirement &gt; 1.2 units/kg/day 3 . Known sensitization rATG ATGAM 4 . Significant renal dysfunction 5 . Significant hepatobiliary disease 6 . Significant cardiovascular disease 7 . Hypertension despite appropriate treatment 8 . Hyperlipidemia despite appropriate treatment 9 . Anemia hematologic disorder require medical treatment . 10 . WBC &lt; 3,000/ul 11 . Increased risk bleeding , chronic hemostasis disorder , treatment chronic anticoagulant therapy 12 . Recent unresolved acute infection ( except mild skin infection nail fungal infection ) , chronic infection 13 . EpsteinBarr Virus ( EBV ) IgG negative 14 . Any history malignancy , except completely resect squamous basal cell carcinoma situ cancer cervix 15 . Recent history noncompliance , inability demonstrate capacity comply strict blood glycemic control insulin therapy 16 . Psychiatric illness untreated , likely interfere significantly study compliance despite treatment 17 . Presence preform antibody panel reactive antibody screen &gt; 25 % 18 . Previous organ/tissue transplant , except noted 19 . Administration live attenuate vaccine within 2 month enrollment 20 . Presence chronic disease must chronically treat contraindicated agent 21 . Use investigational agent within four week enrollment 22 . Active alcohol substance abuse , include cigarette smoking 23 . Pregnant woman , woman intend future pregnancy , woman reproductive potential unable unwilling follow effective contraceptive measure prior study entry long immunosuppression medication , woman presently breast feed exclude 24 . Any medical condition opinion investigator interfere safe participation trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>68 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Islet cell</keyword>
	<keyword>hypoglycemia</keyword>
	<keyword>hypoglycemia unawareness</keyword>
	<keyword>islet kidney transplantation</keyword>
	<keyword>islet transplant</keyword>
	<keyword>insulin independence</keyword>
	<keyword>insulin dependence</keyword>
</DOC>